Abbott Laboratories Third Quarter 2024 Earnings: EPS Beats Expectations

Simply Wall St · 10/18 10:20

Abbott Laboratories (NYSE:ABT) Third Quarter 2024 Results

Key Financial Results

  • Revenue: US$10.6b (up 4.9% from 3Q 2023).
  • Net income: US$1.65b (up 15% from 3Q 2023).
  • Profit margin: 16% (up from 14% in 3Q 2023). The increase in margin was driven by higher revenue.
  • EPS: US$0.94 (up from US$0.82 in 3Q 2023).
earnings-and-revenue-growth
NYSE:ABT Earnings and Revenue Growth October 18th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Abbott Laboratories EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.3%.

Looking ahead, revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are up 2.0% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We have a graphic representation of Abbott Laboratories' balance sheet and an in-depth analysis of the company's financial position.